Epitalon is not FDA-approved. The answer to “is epitalon FDA approved” didn't change with July's favorable committee vote. That vote concerned the 503A bulks list, an FDA ingredient list for medicines prepared for individual prescriptions. It didn't approve a finished medicine or establish a sleep treatment.
Epitalon is a synthetic peptide, a chain made in a lab from four amino acids, the building blocks of proteins. Promise's catalog uses another spelling: Epithalon. Its FDA story runs through nominations, a safety category, withdrawals, a staff review and an advisory vote. Those steps answer different questions.
2018 and 2020: the epitalon 503A nominations
FDA received two nominations asking it to consider epitalon for the ingredient list. LDT Health Solutions submitted one for the International Peptide Society. Its docket record says received November 16, 2018, and posted November 28. A compounding pharmacy's separate nomination was posted December 17, 2020.
The proposed preparations were injections under the skin. FDA evaluated them for insomnia, persistent difficulty getting adequate sleep. The review wasn't an assessment of every longevity claim associated with the molecule.
The submissions also left the ingredient's identity unclear. FDA therefore reviewed two forms: free base, the peptide without an added salt, and acetate, a salt form. A common name on a vial doesn't settle which form it contains.
Even the early history needs care. FDA's briefing document gives “late 1980s” for first synthesis in its chemistry section and 1999 in its historical review. The earlier animal-tissue extract, epithalamin, is a different substance. The discovery story follows that research program and its people.
2023 to April 2026: Category 2, then withdrawal
FDA's category document marked “Updated September 29, 2023” added epitalon to Category 2. This was the agency's interim group for nominated ingredients raising significant safety concerns.
Both nominators withdrew their submissions on April 14, 2026. The pharmacy withdrawal and LDT withdrawal name epitalon explicitly. FDA continued evaluating both forms on its own initiative.
The agency's safety page, marked “Content current as of: 04/22/2026,” now puts epitalon in its withdrawn-nominations table. Its category PDF, marked “Updated May 14, 2026,” lists it in none of the three categories.
That move did not place epitalon in Category 1 or clear the agency's safety questions. The safety page still describes possible immune reactions related to peptide clumping and impurities. For someone considering a prescription, the withdrawal changed the paperwork, not the evidence about the preparation.
May 2026: what FDA staff found
The staff memo carries the date “5/12/2026.” Its conclusion recommended against adding either epitalon form to the list. FDA weighed ingredient identity, historical use, evidence of benefit and safety.
The agency's July 24 presentation lays out the reasons plainly:
| Question | Staff finding |
|---|---|
| Is the ingredient clearly identified? | Names and test results didn't consistently establish which chemical was present or how clean it was. |
| Has it been tested for insomnia? | Staff found no study measuring its effectiveness in people with insomnia. |
| What about injections under the skin? | Staff found no human safety evidence for the proposed route. |
| Do laboratory findings settle the question? | Changes in hormone levels and cells didn't establish better sleep or long-term safety. |
A 2020 study by Ivko and colleagues in Advances in Gerontology reported changes in a urine marker of melatonin, the hormone involved in day-and-night timing. FDA noted that the study didn't measure sleep outcomes. A changed laboratory marker doesn't by itself show that someone slept better.
The familiar Khavinson study in Bulletin of Experimental Biology and Medicine, 2003, tested human cells in a dish. It reported activity of telomerase, an enzyme that rebuilds protective caps on the cell’s genetic material. Those caps are called telomeres. It didn't test sleep treatment in patients. The clinical-trials guide separates those findings from human treatment studies.
July 24, 2026: the epitalon PCAC recommendation
As of September 30, 2026, the day this article was written, FDA's July 24 recording confirms a recommendation to add both forms. The free-base vote and acetate vote each recorded seven in favor, four against and one abstention.
Brian Serumaga, representing the U.S. Pharmacopeia, opposed listing because of unresolved ingredient characterization, meaning how clearly its identity and properties were established. Pharmacist David Pope supported listing and emphasized decisions involving the patient, physician and pharmacist.
The Pharmacy Compounding Advisory Committee, or PCAC, is an outside panel advising FDA. The meeting page, marked “Content current as of: 08/06/2026,” explains that its recommendations are nonbinding. FDA makes the final decision. A favorable vote didn't supply the missing patient studies.
Is epitalon FDA approved? It is not
As of September 30, 2026, the day this article was written, FDA has not published a proposed or final rule adding either form. Its 503A overview still carries “Content current as of: 05/14/2026.” It describes a process of proposed rules, public comments and final rules.
The 503A list explainer describes that process in more detail. An ingredient-list decision and review of a finished drug remain separate matters. The recommendation does not make epitalon FDA-approved.
For a patient, the July recommendation doesn't establish an effective dose, a standard course or a finding about a particular pharmacy's preparation. It also doesn't establish longer human life. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.
Epithalon will be dispensed as a compounded medication, which is different from an FDA-approved product: the formulation Promise will offer is not FDA-approved. Epithalon is coming soon to Promise — add me to the list.
What a prescription visit adds
A visit connects this public record to a particular person's health history, medicines and goals. The clinician considers the evidence and its limits, identifies the proposed preparation and decides whether prescribing makes sense. The prescription and pharmacy label identify what is actually being dispensed.
A licensed U.S. compounding pharmacy supplies an accountable dispensing record and a contact for medication questions. The prescriber remains part of that care relationship. Those are practical differences from a vial sold without a prescription, regardless of what a seller says about the July vote.
At Promise, a licensed U.S. provider reviews every request; not everyone qualifies.
